SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.

Shenzhen Chipscreen Biosciences Co., Ltd.

688321

CNE100003LW0

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
22.19 ^CNY	-1.33%		-6.53%	+1.09%

Apr. 30	National Medical Products Administration Approves Chipscreen Biosciences Co., Ltd.'s Chidamide Combined with R-CHOP for the Treatment of Diffuse Large B-Cell Lymphoma	CI
Apr. 28	Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Shenzhen Chipscreen Biosciences Plans to Buy Property Assets

December 28, 2020 at 05:30 am EST

Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) said it plans to buy property assets for CNY 235.0 million ($35.95 million).

Latest news about Shenzhen Chipscreen Biosciences Co., Ltd.

National Medical Products Administration Approves Chipscreen Biosciences Co., Ltd.'s Chidamide Combined with R-CHOP for the Treatment of Diffuse Large B-Cell Lymphoma	Apr. 30	CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 28	CI
Chipscreen Biosciences Offers Sell-Back Option for Microchip Convertible Bond Holders	Apr. 22	MT
Tranche Update on Shenzhen Chipscreen Biosciences Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.	Apr. 02	CI
Shenzhen Chipscreen Biosciences Co., Ltd. commences an Equity Buyback Plan for CNY 15 million worth of its shares, under the authorization approved on February 22, 2024.	Mar. 26	CI
Shenzhen Chipscreen Biosciences Co., Ltd. Announces Positive Results from Phase II Clinical Trial (CGZ203 Study) of Chiglitazar Monotherapy for Non-Alalcoholic Steatohepatitis	Mar. 18	CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Chipscreen Biosciences' New Production Line Passes Regulatory Inspection	Nov. 23	MT
Chipscreen Biosciences Gets Regulatory Nod for China Clinical Trial of Psoriasis Drug	Nov. 01	MT
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Shenzhen Chipscreen Biosciences Co., Ltd.(XSSC:688321) added to S&P Global BMI Index	23-09-18	CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-11	CI
Chinese Drug Regulator to Prioritize Shenzhen Chipscreen Biosciences' Application for Chidamide Tablets	23-07-21	MT
Shenzhen Chipscreen Biosciences Gets Nod for Tumor Drug Trial	23-06-27	MT
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Shenzhen Chipscreen Biosciences' Diabetes Drug Placed in 2022 Chinese Drug Catalogue	23-01-20	MT
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Shenzhen Chipscreen Biosciences Co., Ltd. announced that it expects to receive CNY 260 million in funding	22-08-04	CI
Certain A Shares of Shenzhen Chipscreen Biosciences Co., Ltd. are subject to a Lock-Up Agreement Ending on 2-AUG-2022.	22-08-01	CI
Shenzhen Chipscreen Biosciences Co., Ltd.(SHSE:688321) dropped from Shanghai Stock Exchange Health Care Sector Index	22-06-10	CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Shenzhen Chipscreen Biosciences Co., Ltd.'s Equity Buyback announced on July 7, 2021, has expired.	22-04-18	CI
Akeso, Chipscreen Bio to Jointly Carry Out Clinical Trials of Combination Therapy for Lung Cancer	22-03-02	MT
Akeso, Inc. Announces Collaboration with Chipscreen Biosciences to Initiated A Clinical Trial of Pd-1/Ctla-4 Bi-Specific Antibody in Combination with Chiauranib for Pd-(L)1 Pretreated Es-Sclc	22-03-02	CI

Chart Shenzhen Chipscreen Biosciences Co., Ltd.

Duration

Period

Chart Shenzhen Chipscreen Biosciences Co., Ltd.

More charts

Shenzhen Chipscreen Biosciences Co Ltd is a China-based company mainly engaged in the research and development of original innovative drugs. The Company focuses on the research and development of original innovative drugs in five therapeutic areas, including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases and anti-virus. The Company's main products include Chidamide, Siglitazone, Cioroni and CS12192. The Company mainly conducts its businesses in the domestic market.

Sector

Pharmaceuticals

Calendar

2024-07-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Shenzhen Chipscreen Biosciences Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.19 CNY

Average target price

31.64 CNY

Spread / Average Target

+42.59%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.	+1.09%	1.25B
MERCK KGAA	+14.95%	78.22B
KYOWA KIRIN CO. LTD.	+8.25%	8.84B
SK BIOPHARMACEUTICALS CO., LTD.	-12.05%	5.07B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+53.66%	4.82B
YUHAN CORPORATION	+11.63%	4.2B
BETTA PHARMACEUTICALS CO., LTD.	-23.67%	2.28B
INDIVIOR PLC	+11.39%	2.28B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-32.35%	2.12B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+21.04%	2.2B

Specialty & Advanced Pharmaceuticals

Shenzhen Chipscreen Biosciences Co., Ltd.

Equities

688321

CNE100003LW0

Pharmaceuticals

Shenzhen Chipscreen Biosciences Plans to Buy Property Assets

Latest news about Shenzhen Chipscreen Biosciences Co., Ltd.

Chart Shenzhen Chipscreen Biosciences Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Shenzhen Chipscreen Biosciences Co., Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals